In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Serono and InDex Pharmaceuticals develop colitis therapy; deal later terminated

Executive Summary

InDex Pharmaceuticals AB (develops antisense therapeutics and diagnostics for inflammatory diseases and cancer) licensed Serono SA (drugs with a focus on neurology, metabolism, and growth) exclusive development and marketing rights to Kappaproct, an antisense compound in Phase II trials to treat active ulcerative colitis.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies